Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven in PNALD
NCT01565278Phase 3Terminated
- Start
- Feb 2012
- Primary completion
- Aug 2015
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD). Started Feb 2012; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT01565278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565278.